Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.55 |
| ▸ | SRC | P12931 | 9/20 | 0.49 |
| ▸ | STK4 | Q13043 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4742017 | 0.89 | SRC (0.59) | EGFRERBB2SRCSTK4 | |
| SCHEMBL2965914 | 0.86 | SRC (0.55) | EGFRERBB2SRC | |
| SCHEMBL6182177 | 0.86 | SRC (0.52) | EGFRERBB2SRC | |
| SCHEMBL6381695 | 0.84 | SRC (0.62) | EGFRERBB2SRC | |
| SCHEMBL5459297 | 0.84 | SRC (0.62) | EGFRERBB2SRC | |
| SCHEMBL6185302 | 0.82 | EGFR (0.46) | EGFRERBB2SRC | |
| SCHEMBL13503087 | 0.82 | SRC (0.49) | EGFRERBB2SRCSTK4 | |
| SCHEMBL15263291 | 0.81 | SRC (0.41) | EGFRERBB2SRC | |
| SCHEMBL20775158 | 0.81 | SRC (0.55) | EGFRERBB2SRC | |
| SCHEMBL31506316 | 0.78 | SRC (0.45) | EGFRERBB2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449460-B2 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1594502-A1 | 4- (2,4-DICHLORO-5-METHOXYPHENYL)AMINO -6-ALKOXY-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | Wyeth (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005082891-A1 | -QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050187247-A1 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| EP-1499594-B1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | WYETH CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005047259-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | WYETH (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005047259-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | WYETH (US) | 2005-05-26 | — | — | WO | disclosed |
| EP-1499594-A1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | Wyeth Holdings Corporation (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040229880-A1 | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury | WYETH | 2004-11-18 | — | — | US | disclosed |
| WO-2004075898-A1 | 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | WYETH (US) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004075898-A1 | 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | WYETH (US) | 2004-09-10 | — | — | WO | disclosed |
| US-6780996-B2 | KINASE INHIBITORS; ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION | 2004-08-24 | — | — | US | disclosed |
| US-20030212276-A1 | Process for the preparation of 7-substituted-3 quinolinecarbonitriles | WYETH HOLDINGS CORPORATION | 2003-11-13 | — | — | US | disclosed |
| WO-2003093241-A1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | WYETH HOLDINGS CORPORATION (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212276-A1 | Process for the preparation of 7-substituted-3 quinolinecarbonitriles | MAP4K2, MAP3K7, MAP4K1 | EGFR 1394/4885ERBB2 395/4885SRC 386/4885 |
| US-20040229880-A1 | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury | TNNI3, TXN2, AIFM1 | EGFR 3647/4885ERBB2 3386/4885SRC 4373/4885 |
| US-20050187247-A1 | 3-Quinolinecarbonitrile protein kinase inhibitors | RAF1, KRAS, NRAS | EGFR 895/4885ERBB2 885/4885SRC 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.